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Depression in multiple sclerosis (MS) is common 
(24%)1 and has a large impact on quality of life. It is 
related to fatigue, cognitive dysfunction, working 
problems and disrupted social support and family sys-
tems and may adversely affect health outcome.2,3 
Cognitive behavioral therapy (CBT) is an effective 
treatment for depressed patients with medical condi-
tions including MS.4,5 Still, many MS patients remain 
untreated.3 Under-treatment may be due to disease-
related barriers such as transportation difficulties, 
physical immobility, fatigue and MS exacerbations 
that impede face-to-face treatment.6
Guided Internet-based cognitive behavioral therapy 
(ICBT) is considered a good alternative for face-to-
face treatment.7,8 ICBT is easily available, cost-
effective, and can reach a large number of people with 
functional impairments due to physical health prob-
lems. Internet-based interventions demonstrated psy-
chosocial benefits in chronic illness settings,9 and 
research of telemedicine technologies in treating 
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Abstract
Background: Depression in multiple sclerosis (MS) patients is common but may stay untreated. Physi-
cal limitations impede face-to-face treatment. Internet-based treatment is therefore a promising tool for 
treating depression in MS.
Objectives: To investigate effectiveness of a guided Internet-based problem-solving treatment (IPST) for 
depressed MS patients.
Methods: MS patients with moderate or severe depressive symptoms were randomly assigned to IPST 
or a wait list control. Primary outcome was the change in depressive symptoms defined by a change in 
sum score on the Beck Depression Inventory Second Edition (BDI-II). Assessments took place at baseline 
(T0), within a week after the intervention (T1), and at 4 months follow-up (T2). Analyses were based on 
the intention-to-treat principle.
Results: A total of 171 patients were randomized to IPST (n = 85) or a wait list control (n = 86). T1 was 
completed by 152 (89%) and T2 by 131 patients (77%). The IPST group and wait list control showed 
large significant improvements in depressive symptoms, but no differences were found between groups at 
T1 (d = 0.23; 95% confidence interval (CI) = (−4.03, 1.08); p = 0.259) and T2 (d = 0.01; 95% CI = (−2.80, 
2.98); p = 0.953).
Conclusion: We found no indication that IPST for MS patients with moderate or severe depression is 
effective in reducing depressive symptoms compared to a waiting list. Large improvements in the wait list 
control were unexpected and are discussed.
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depression in (housebound) MS patients was recently 
advised in MS guidelines.3 Although this patient group 
may likely benefit from ICBT, there are still few publi-
cations on ICBT for depressed MS patients,10–12 and 
the results are encouraging. In an uncontrolled pilot 
study, we found that Internet-based problem-solving 
treatment (IPST), CBT with a focus on developing suf-
ficient coping skills, is a feasible treatment for depres-
sion in MS and may reduce depressive symptoms.10
Here, we present a randomized controlled trial (RCT) 
to investigate the effectiveness of guided IPST for 
depression in MS.13 We aimed to examine effective-
ness of IPST on the primary outcome measure depres-
sive symptoms and on secondary outcome measures 
related to depression in MS such as anxiety, quality of 
life, fatigue, cognitive, and physical functioning.
Patients and methods
Trial design
A two-armed RCT in which an Internet-based guided 
self-help problem-solving treatment (IPST) was com-
pared with a wait list control. An extensive descrip-
tion of the study protocol can be found elsewhere.13 
The trial was approved by the Medical Ethics 
Committee of the VU University Medical Center and 
registered with the Dutch Trial Registry (NTR2772).
Patients
MS patients were recruited at several MS centers 
throughout the Netherlands, and through calls in MS 
newsletters and Internet sites, and were invited to 
complete an online screening assessment. Patients 
(18 years or older) with sufficient command of Dutch 
language and Internet access were eligible to partici-
pate if they had (a) a diagnosis of MS (>3 months) and 
(b) a score of 20 or more on the Beck Depression 
Inventory Second Edition (BDI-II), indicating moder-
ate or severe depression. Patients taking prescribed 
psychotropic medication for more than 6 weeks with 
stable dosage were allowed to participate. Those 
receiving psychotherapy or with an elevated risk for 
suicide assessed with item 9 of the BDI-II and an 
additional telephone interview were excluded. All 
patients gave written informed consent.
IPST
The guided self-help intervention “Minder Zorgen” 
(“Worry Less”) was an existing and tested IPST that 
was adjusted for MS patients.13 The intervention con-
sisted of five sequential modules with text, examples 
and assignments that patients could access from their 
personal computers via the Internet. Patients were 
advised to complete one module per week but could 
extend the intervention period up to 10 weeks if extra 
time was needed. Support during the intervention was 
provided by trained psychologists and supervised 
psychology master students and consisted of weekly 
emails. Patients could contact their coach at any 
moment for additional support via the website. 
Support was directed to help the patient work through 
the intervention.
Patients randomized to the wait list control received 
no IPST. After completion of the 4 months follow-up 
assessment, they were offered the possibility to par-
ticipate in the intervention.
Outcomes
Eligible and consenting patients were assessed at 
baseline (T0), within a week after the intervention 
(5–10 weeks) (T1), and at 4 months follow-up (T2). 
The wait list control was measured at the same 
moments in time. Data were collected by self-report 
measures administered through the Internet and a tel-
ephone interview at baseline by trained research staff.
The primary outcome was the change in depressive 
symptoms defined by a change in sum score on the 
BDI-II. Post hoc analyses for BDI-II subscale scores14 
and for moderate (BDI-II = 20–28) and severely 
(BDI-II ⩾ 29) depressed patients at baseline were 
additionally performed (supplementary material). 
Secondary outcome measures were the anxiety sub-
scales of the Hospital Anxiety and Depression Scale, 
Beck Anxiety Inventory, Fatigue Severity Scale, 
Multiple Sclerosis Neuropsychological Questionnaire, 
Multiple Sclerosis Impact Scale, EuroQol quality of 
life measure, subscales of the Social Problem Solving 
Inventory-Revised, and the abbreviated version of the 
Pearlin Mastery Scale.
At baseline, a clinical diagnosis of a Depression 
Disorder and/or Anxiety Disorder according to 
Diagnostic and Statistical Manual of Mental 
Disorders (Fourth Edition, Text Revision; DSM-
IV-TR) criteria was established by a standard tele-
phone interview using the Composite International 
Diagnostic Interview. The telephone version of the 
Expanded Disability Status Scale was used to assess 
physical (MS) functioning and disability level. Other 
additional baseline measures concerned socio-
demographic and MS-specific questions. Patients’ 
neurologists gave written confirmation of the MS 
diagnosis. Finally, the use of psychotherapy and/or 
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psychotropic medication since baseline assessment 
was registered, and satisfaction of received care and 
text messages (if applicable) was measured with the 
Client Satisfaction Questionnaire (CSQ) and evalua-
tive questions using Visual Analogue Scale (VAS). 
Adverse events were assessed post hoc by deteriora-
tion (increase in significant depression severity; 
exceeding the lower threshold for suicidal ideation: 
score > 1 on BDI-II item 9) and non-response (no clin-
ically significant change or deterioration).11,15 More 
extensive information can be found in the protocol.13
Sample size
The power calculation was based on the comparison 
of T1 to T0 between the two groups. To demonstrate 
moderate effects (Cohen’s d = 0.5) on the primary out-
come measure (depressive symptoms), while using a 
power 0.80, with alpha set at 0.05 (two-tailed), a total 
set of n = 64 patients was needed in each condition. 
Taking into account an anticipated dropout percent-
age (about 25%), at least 166 patients had to be 
included to certify sufficient power.13
Randomization and blinding
Patients were randomized by an independent 
researcher after baseline, using a blocked randomiza-
tion scheme. A randomly allocated number of patients 
who took part in the intervention received four weekly 
supportive text messages on their mobile phones 
aimed to enhance treatment adherence. Text messages 
were in addition to the email support that was received 
by every patient in the IPST group. Patients were 
informed about their assignment by the first author 
(R.E.S.). Due to the nature of the intervention, neither 
patients nor providers of support could be blinded for 
the intervention. Randomization and statistical analy-
sis were performed blindly.
Statistical analyses
Analyses were based on the intention-to-treat principle. 
T-tests and chi-square tests were used to investigate 
baseline differences in demographic and clinical vari-
ables between both arms. Linear mixed model (LMM) 
analyses were conducted through a marginal model to 
evaluate the difference in depressive symptoms (pri-
mary outcome) and secondary outcomes between the 
IPST group and wait list control. LMM analysis is able 
to handle missing data due to dropout under the 
assumption that missing data are missing at random.16 
We used an LMM analysis due to progressive insight 
and deviated from the statistical method described in 
our protocol (last observation carried forward method 
and regression imputation). Furthermore, a subgroup 
analysis was performed using the same procedure as in 
the intention-to-treat analyses with patients who ful-
filled criteria for treatment adherence (at least three 
modules completed). Cohen’s17 formula was used to 
calculate effect sizes for the estimated differences.18 
The standardized method of Jacobson and Truax19 was 
used to determine clinically significant improvement, 
deterioration, and recovery. Recovery was defined as 
reliable change plus a score of 13 or lower on the 
BDI-II.14 Finally, descriptive statistics and a chi-
square test were used to explore the feasibility of text 
messages as a way to increase compliance to the inter-
vention. Data were analyzed using IBM SPSS statistics 




From July 2011 to August 2015, 495 MS patients 
were assessed for eligibility, of whom, 171 were ran-
domized to IPST (n = 85) or wait list control (n = 86) 
(Figure 1). In all, 19 patients (11%) did not complete 
T1—11 patients in the IPST group and 8 patients in 
the wait list control. At T2, another n = 21 (12%) 
patients dropped out, leaving n = 64 (75%) patients in 
the IPST group and n = 67 (78%) in the wait list con-
trol. Dropout rates were not differential with respect 
to IPST versus wait list control at T1 (p = 0.449) and 
T2 (p = 0.687). Average time of T1 was 9 weeks (IPST; 
9.1 ± 2.6/wait list control; 9.2 ± 2.5). Baseline demo-
graphics and clinical characteristics were much the 
same between the IPST group and wait list control 
and are displayed in Table 1.
Differences in baseline characteristics were assessed 
for patients who completed T1 and those who did not. 
Non-completers had a higher mean BDI-II score 
(30.6 ± 7.3 versus 27.3 ± 6.3; p = 0.035) and were more 
often taking anti-depressant medication (16% versus 
13%; p = 0.032).
Adherence
A total of 57 out of 85 patients (67%) completed at 
least three modules and were considered treatment 
completers (mean number of modules for treatment 
completers was 4.58 ± 0.78 versus 1.07 ± 0.77 for non-
completers). Treatment completers had a lower mean 
age than non-completers (46.2 ± 10.4 versus 
52.9 ± 11.3; p = 0.008) but did not differ in gender, 
education level, disability level, and depression sever-
ity at baseline. Main reasons for dropout were 
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computer-related problems (n = 5/28), lack of time 
(n = 7/28), the intervention not meeting patients’ 
needs/starting other treatment (n = 11/28), MS-related 
problems such as pain, vision problems, or hospitali-
zation (n = 5/28).
In total, 40 patients in the IPST arm were allocated to 
receive additional text messages. Four patients 
refused these text messages (unfamiliar with/no 
mobile phone (n = 2) or not useful (n = 2)). Additional 
text messages did not increase the compliance rate of 
the intervention (three or more modules completed) 
compared with no text messages (65% versus 69%; 
p = 0.703).
Healthcare use
From baseline to T1, there was no difference in 
healthcare use between the IPST and wait list control: 
18% versus 13% contacted a psychologist or psychia-
trist (p = 0.414), and 15% versus 17% used anti-
depressants (p = 0.258).
Effects
Improvement on outcome measures. Results of the 
intention-to-treat analyses are displayed in Tables 2 
and 3. A high within-group effect size was found for 
the primary outcome of depressive symptoms for 
IPST (d = 1.18; 95% confidence interval (CI) = (0.88, 
Figure 1. Flow diagram.
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Table 1. Baseline demographics and clinical characteristics.
All patients (n = 171) IPST (n = 85) Wait list control (n = 86)
 Mean (SD) or % Mean (SD) or % Mean (SD) or %
Demographics
Age, years 48.9 (10.5) 48.4 (11.1) 49.4 (9.9)
Gender, women 80.1 83.5 76.7
Country of birth
 The Netherlands 93.6 94.1 93.0
 Other 6.4 5.9 7.0
Educationa
 Low 1.2 0.0 2.3
 Middle 53.2 56.5 50.0
 High 45.6 43.5 47.7
Marital status
 Relationship, yes 78.4 72.9 83.7
MS characteristics
Years since MS onset 11.2 (8.1) 11.1 (8.3) 11.3 (8.0)
Type of MS (by neurologist)
 Benign 2.3 3.5 1.2
 Relapsing remitting 55.0 54.1 55.8
 Secondary progressive 28.1 25.9 30.2
 Primary progressive 9.9 9.4 10.5
 Relapsing progressive 3.5 4.7 2.3
 Missing 1.2 2.4 0.0
EDSS (n = 170)
 0–1.5 3.5 4.7 2.3
 2–4 50.9 48.2 53.5
 4.5–6 17.5 18.8 16.3
 ⩾6.5 27.5 27.1 27.9
Medication
 MS disease-modifying (n = 152) 32.9 36.5 29.5
 MS symptom relief (n = 152) 52.0 48.6 55.1
 Anti-depressants, yes 12.9 11.8 14.0
Diagnoses
Depressive disorder
 First episode (major depressive disorder (MDD)) 58.5 53.4 63.3
 Current depressive disorder 55.0 56.5 53.5
  MDD 52.0 50.6 53.5
  Dysthemia 2.9 5.9 0.0
 Lifetime depressive disorder (MDD and/or dysthemia) 71.3 72.9 69.8
Anxiety disorder
 Current 31.8 30.6 32.9
 Lifetime 41.2 35.3 47.1
Comorbid depressive and anxiety disorder
 Current 20.1 18.8 21.4
 Lifetime 32.9 28.2 37.6
Symptom severity
 Depression (BDI-II) 27.7 (6.4) 28.2 (6.6) 27.3 (6.3)
 Anxiety (HADS) 10.4 (3.2) 10.4 (3.2) 10.5 (3.2)
IPST: Internet-based problem-solving treatment; MS: multiple sclerosis; EDSS: Expanded Disability Status Scale: 0–1.5 = no complaints, 2–4 = low-to-moderate 
complaints, 4–6 = moderate-to-severe complaints, ⩾6.5 = very severe complaints; BDI-II: Beck Depression Inventory Second Edition; HADS: Hospital Anxiety 
and Depression Scale; SD: standard deviation.
a Low: primary education, middle: lower general secondary education, intermediate vocational education or high school, high: higher vocational education or 
university.
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1.47)) and wait list control (d = 0.95; 95% CI = (0.67, 
1.23)) at T1, and for IPST (d = 1.11; 95% CI = (0.78, 
1.43)) and wait list control (d = 1.12; 95% CI = (0.80, 
1.44)) at T2. No significant difference between groups 
was found at T1 (d = 0.23; 95% CI = (−4.03, 1.08); 
p = 0.259) or at T2 (d = 0.01; 95% CI = (−2.80, 2.98); 
Table 2. Mean scores for primary and secondary outcomes for the IPST group at T0 (n = 85), T1 (n = 74), and T2 (n = 64) 
and the wait list control at T0 (n = 86), T1 (n = 78), and T2 (n = 67).
IPST Wait list control
 Mean (SD) Mean (SD)
Primary outcome
Depression (BDI-II) T0 28.2 (6.3) 27.2 (6.6)
 T1 20.3 (8.8) 21.0 (9.1)
 T2 20.8 (10.4) 20.1 (9.2)
Secondary outcomes
Anxiety (HADS-A) T0 10.4 (3.2) 10.4 (3.2)
 T1 9.0 (3.8) 9.3 (3.8)
 T2 8.8 (3.8) 8.9 (3.8)
Anxiety (BAI) T0 18.4 (8.8) 18.5 (0.9)
 T1 15.7 (9.0) 17.4 (11.1)
 T2 16.3 (10.1) 17.1 (11.0)
Fatigue (FSS) T0 5.8 (1.0) 5.8 (0.9)
 T1 5.7 (0.9) 5.7 (0.9)
 T2 5.7 (1.0) 5.6 (1.1)
Cognitive functioning (MSNQ) T0 30.6 (10.9) 31.0 (10.1)
 T1 28.7 (10.5) 29.7 (10.0)
 T2 28.0 (10.4) 29.2 (9.8)
Physical and psychological impact of 
MS (MSIS-29) 
T0 89.8 (22.8) 87.6 (21.1)
T1 82.9 (22.8) 82.6 (23.3)
 T2 84.6 (25.0) 82.6 (32.2)
Quality of life (EQ-5D) T0 0.47 (.3) 0.51 (.3)
 T1 0.52 (.3) 0.58 (.3)
 T2 0.46 (.4) 0.57 (.3)
Quality of life (EQ-VAS) T0 57.7 (17.8) 58.1 (17.8)
 T1 59.1 (17.9) 59.9 (17.4)
 T2 58.0 (19.5) 60.4 (18.2)
Problem-solving skills (SPSI-R npo) T0 19.2 (7.8) 19.4 (7.4)
 T1 15.7 (7.3) 16.8 (7.6)
 T2 17.5 (7.0) 17.1 (7.3)
Problem-solving skills (SPSI-R ppo) T0 9.4 (3.6) 9.4 (3.4)
 T1 10.1 (3.5) 9.6 (3.4)
 T2 9.5 (3.4) 10.3 (3.5)
Problem-solving skills (SPSI-R av) T0 10.6 (5.9) 11.1 (5.5)
 T1 8.8 (6.0) 10.3 (5.8)
 T2 10.2 (6.2) 10.1 (5.1)
Mastery (Pearlin Mastery Scale) T0 13.1 (3.7) 13.1 (3.5)
 T1 13.6 (3.6) 13.4 (3.7)
 T2 12.6 (4.0) 14.1 (4.5)
IPST: Internet-based problem-solving treatment; BDI-II: Beck Depression Inventory Second Edition; HADS-A: Hospital Anxi-
ety and Depression Scale–Anxiety subscale; BAI: Beck Anxiety Inventory; FSS: Fatigue Severity Scale; the scale ranged from 1 
(strongly disagree with the statement) to 5 (strongly agree with the statement) instead of 1 (strongly disagree with the statement) 
to 7 (strongly agree with the statement) and was therefore recoded (1 = 1; 2 = 2.5; 3 = 4; 4 = 5.5; 5 = 7); MSNQ: Multiple Sclerosis 
Neuropsychological Questionnaire; MSIS-29: Multiple Sclerosis Impact Scale-29; EQ-5D: EuroQol quality of life measure; EQ-
VAS; EuroQol quality of life measure–Visual Analogue Scale; SPSI-R: Problem Solving Inventory-Revised; npo: negative problem 
orientation scale; ppo: positive problem orientation scale; av: avoidance scale; SD: standard deviation.
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p = 0.953) (Figure 2). Also, no significant difference 
was found when comparing IPST completers (n = 57; 
greater than or equal to three modules) with the wait 
list control at T1 (d = 0.34; 95% CI = (−5.06, 0.693); 
p = 0.136) or at T2 (d = 0.05; 95% CI = (−3.51, 2.81); 
p = 0.828). BDI-II post hoc analyses showed no sig-
nificant differences between IPST and the wait list 
control at T1 and T2 in subscale scores and for 
severely depressed patients versus moderate depressed 
patients (supplementary material).
For the secondary analyses, there was a difference 
between the two groups at T2 for mastery (d = 0.34; 
t(169) = −2.294; p = 0.023) in favor of the wait list 
control which should be interpreted, however, as a 
negligible finding due to multiple testing. No other 
significant differences were found between groups at 
different time points.
Clinical significant improvement and recovery. Based 
on the reliable change index (at least 5-point decrease 
in the BDI-II),19 66% (=49/74) in the IPST group and 
53% (=41/78) in the wait list control showed a signifi-
cant improvement in depressive symptoms at T1 
(p = 0.087) and 63% (40/64) versus 60% (40/67) at T2 
(p = 0.743). In the IPST group, 24% (=18/74) was 
Table 3. Test statistics and effect sizes of the differences in primary and secondary outcomes between the IPST group 
and wait list control, from linear mixed model analyses.
t p-value Effect size (d)
Primary outcome
Depression (BDI-II) Condition * T1 −1.133 0.259 0.23
 Condition * T2 0.060 0.953 0.01
IPST completers (n = 57) Condition * T1 −1.501 0.136 0.34
 Condition * T2 −0.218 0.828 0.05
Secondary outcomes
Anxiety (HADS-A) Condition * T1 −0.743 0.458 0.11
 Condition * T2 −0.298 0.766 0.05
Anxiety (BAI) Condition * T1 −1.654 0.100 0.20
 Condition * T2 −0.260 0.795 0.04
Fatigue (FSS) Condition * T1 −0.976 0.331 0.17
 Condition * T2 0.502 0.617 0.12
Cognitive functioning (MSNQ) Condition * T1 −0.611 0.542 0.06
 Condition * T2 −0.358 0.721 0.04
Physical and psychological impact of 
MS (MSIS-29)
Condition * T1 −0.360 0.719 0.03
 Condition * T2 0.395 0.694 0.00
Quality of life (EQ-5D) Condition * T1 −0.932 0.353 0.13
 Condition * T2 −1.686 0.094 0.29
Qualty of life (EQ-VAS) Condition * T1 −0.255 0.799 0.04
 Condition * T2 −0.507 0.613 0.09
Problem-solving skills (SPSI-R npo) Condition * T1 −1.132 0.259 0.14
 Condition * T2 −0.159 0.874 0.02
Problem-solving skills (SPSI-R ppo) Condition * T1 0.772 0.441 0.10
 Condition * T2 0.251 0.802 0.20
Problem-solving skills (SPSI-R av) Condition * T1 −1.385 0.168 0.16
 Condition * T2 0.466 0.642 0.06
Mastery (Pearlin Mastery Scale) Condition * T1 0.670 0.504 0.09
 Condition * T2 −2.294 0.023 0.34
IPST: Internet-based problem-solving treatment; BDI-II: Beck Depression Inventory Second Edition; HADS-A: Hospital Anxi-
ety and Depression Scale–Anxiety subscale; BAI: Beck Anxiety Inventory; FSS: Fatigue Severity Scale; the scale ranged from 1 
(strongly disagree with the statement) to 5 (strongly agree with the statement) instead of 1 (strongly disagree with the statement) 
to 7 (strongly agree with the statement) and was therefore recoded (1 = 1; 2 = 2.5; 3 = 4; 4 = 5.5; 5 = 7); MSNQ: Multiple Sclerosis 
Neuropsychological Questionnaire; MSIS-29: Multiple Sclerosis Impact Scale-29; EQ-5D: EuroQol quality of life measure; EQ-
VAS; EuroQol quality of life measure–Visual Analogue Scale; SPSI-R: Problem Solving Inventory-Revised, npo: negative problem 
orientation scale; ppo: positive problem orientation scale; av: avoidance scale.
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recovered from depressive symptoms at T1 versus 
18% (=14/78) in the wait list control which did not 
differ significantly (p = 0.335). At T2, 28% of patients 
(=18/64) were recovered in the IPST group versus 
26% (=17/67) in the wait list control (p = 0.722).
Satisfaction and adverse events
In line with positive evaluations of other ICBT,8,20 the 
majority of IPST patients (n = 73) were satisfied (as 
measured with the CSQ) with the help they had 
received (89%) and would recommend this kind of 
treatment to others (71%). A total of 80% rated the 
quality of the intervention as good or excellent, and 
the majority thought that the intervention helped them 
to deal with their problems (66%). The website was 
rated with an average of 7.2 ± 1.3 on a 10-point VAS, 
and most patients indicated that the website was clear 
(74%) and easy to use (77%). The majority was satis-
fied with the frequency of the feedback (85%) and 
rated its quality as good or excellent (78%).
We found no evidence of adverse events as a conse-
quence of IPST. Post hoc analyses showed no signifi-
cant difference with regard to the proportion of 
patients reporting significant deterioration for IPST 
(7/74) compared with the wait list control at T1 (5/78; 
p = 0.486). The threshold for suicidal ideation was met 
by one patient in the IPST group and two patients in 
the wait list control. Non-response was not signifi-
cantly different for IPST (34%; 25/74) versus the wait 
list control (47%; 37/78).
Discussion
MS patients with moderate or severe depression 
treated with guided IPST showed a large decrease in 
depressive symptoms that sustained over 4 months 
follow-up. A similar improvement was observed in 
the wait list control. Therefore, we found no indica-
tion that IPST is more effective than a waiting list.
Our findings contrast the result of a study executed in 
Germany showing effectiveness of ICBT (Deprexis) 
for depression in MS.11 Both interventions studied are 
based on the principles of CBT. “Minder Zorgen” 
consisted of five sequential modules of problem-solv-
ing therapy (PST) with guided email support, whereas 
the fully automated “Deprexis” offers 9-week access 
to 10 modules with other CBT techniques next to 
problem solving. However, within-group effect sizes 
found for both interventions were substantial (medium 
for “Deprexis,” large for “Minder Zorgen”), suggest-
ing explanations for different between-group findings 
should not be attributed to the intervention per se.
The considerable decrease in depressive symptoms in 
our wait list control was unexpected and does not cor-
respond with findings from (I)CBT trials for depres-
sion in MS5,11 or with literature on ICBT for depression 
in general.8 Our findings of significant improvement 
in both arms, including the wait list control, resemble 
outcomes of several studies comparing ICBT with a 
wait list control for depressed outpatients, employees, 
or patients in a community sample.21–24 Our results 
were unexpected, and various explanations can be 
suggested.
First, clarification of our findings is unlikely to be 
found in the chosen study design, as the use of wait list 
controls often results in largest trial effect sizes.25 In 
addition, we performed a high-quality trial with inde-
pendent randomization and intention to treat analyses. 
The large number of participating patients and low 
dropout rates (11%) are major strengths of our study. 
Second, our tested intervention is considered suffi-
cient; the decrease in depressive symptoms in the 
intervention group was as expected, and improvement 
and satisfaction rates correspond to similar studies and 
our pilot.10,20 However, participants had moderate or 
severe depressive symptoms, where most ICBT stud-
ies have focused on mild-to-moderate depression.8,11,20 
Although ICBT for more severely depressed is still a 
field to explore,8,20 previous findings suggest that 
more severely depressed could benefit as much from 
low-intensity interventions or ICBT as less severely 
depressed10,26,27 which is also supported by our post 
hoc analysis. Third, decreased depressive symptoms 
could be MS related, as the BDI may measure symp-
toms of the physical condition along with symptoms 
of depression. However, most of these symptoms are 
unlikely to change significantly over the course of a 
relatively short period, and the BDI is suggested to be 
an adequate measure for depression in MS.3,28 Also, 
Figure 2. Depressive symptoms for the intervention 
group (IPST = Internet-based problem-solving treatment) 
and wait list control at baseline (T0), T1 (after the 
intervention), and T2 (4 months follow-up).
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post hoc analyses showed no difference in BDI-II sub-
scale outcomes between groups over time. Fourth, 
another explanation for improvement in the wait list 
control might be recruitment of highly motivated 
patients (the majority of patients applied themselves) 
who are willing to address their complaints, resulting 
in improvement accordingly. Even a small degree of 
contact with a clinician (e.g. interview) seems to lead 
to better (treatment) outcomes.29 Fifth, around 15% of 
patients in both arms received mental healthcare out-
side our trial which could have affected results. 
Outcomes for completers receiving no other mental 
healthcare between baseline and T1 and T2 were 
therefore additionally compared. Large improvement 
in depressive symptoms in the IPST group and wait 
list control remained, and no significant differences 
were observed (supplementary material). Finally, 
decreased depression symptomatology in the wait list 
control could be a result of regression to the mean as 
high scores are more likely to decrease. It may repre-
sent the natural course of depressive symptoms in 
MS patients. In the general population, half of 
depressed patients recover within 3 months,30 which 
may also apply to the MS population stressing the 
importance to distinguish between adaptive (nega-
tive) emotions that improve over time and persisting 
emotional disorders with a need for treatment in this 
patient group.
Altogether, instead of an effect of the intervention, 
results showed an effect over time in both arms which 
should probably not be attributed to the study design, 
depression severity and assessment, or additional 
care. We feel that the explanation should be sought in 
spontaneous recovery of a highly motivated subsam-
ple of patients. ICBT may be a helpful intervention 
for depressed MS patients, but it probably has no 
added value in a select group of motivated patients. 
As findings on ICBT for depression in MS are incon-
sistent, more research is advised.
Even though large effect sizes were found within the 
two arms, around 75% of patients were not recovered 
at T1 and T2. Non-recovery may be due to high 
depression severity at baseline,26,30 to low-intensity 
treatment, or might have to do with the MS-related 
depression itself that is suggested to be static31 and 
more difficult to treat.32 If MS-related depression is a 
more complex persistent condition, it is unrealistic to 
expect recovery from a single intervention, and com-
bined treatment options should be considered.33 Since 
persistent residual depressive symptoms increase the 
risk of relapse and poor functional and psychosocial 
outcomes,34 it is essential to further identify and 
understand non-recovery of depressed MS patients 
and adjust treatment accordingly.26,30
There are several limitations of our study. First, 
although the clinical interview at baseline is a strength 
of our study, it was not performed at T1/T2. 
Consequently, conclusions are based on self-reported 
depression that may be prone to bias. Second, adher-
ence rates of our intervention were substantially lower 
compared with face-to-face treatments.20 Our effort to 
increase treatment adherence by adding telephone 
support (text messages) did not lead to the desired 
effect. Low ICBT adherence rates are a serious point 
of concern.35 However, treatment adherence for MS 
patients was comparable or better compared with 
other ICBT interventions,20,23,24 which is encouraging 
as lower rates could have been expected due to 
MS-related complaints interfering with treatment.12
Further research is thus needed to understand deter-
minants of (I)CBT response, adherence, and (disease-
related) characteristic of depressed MS patients who 
may benefit from it. Potential advantages of combin-
ing ICBT with face-to-face treatment should be inves-
tigated as well as combinations with other treatments 
(e.g. medication).33
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